MREO250117P5500
- 0.00
- 0.000.00%
Mereo BioPharma Newsroom
Mereo BioPharma Group Initiated at Outperform by LifeSci Capital
LifeSci Capital Initiates Mereo BioPharma(MREO.US) With Buy Rating, Announces Target Price $10
Mereo Biopharma's Potential in Rare Disease Therapy: Buy Rating and Strategic Partnership With Ultragenyx
Mereo BioPharma Group Analyst Ratings
Jefferies Initiates Mereo BioPharma(MREO.US) With Buy Rating, Announces Target Price $7
Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE), Mereo Biopharma Group Plc (MREO) and Fate Therapeutics (FATE)
BTIG Maintains Mereo BioPharma(MREO.US) With Buy Rating, Maintains Target Price $6
Needham Maintains Mereo BioPharma(MREO.US) With Buy Rating, Maintains Target Price $7
Needham Reiterates Buy on Mereo BioPharma Group, Maintains $7 Price Target
Mereo Biopharma Group: Anticipated Positive Developments and Strong Financial Position Justify Buy Rating
Baird Maintains Mereo BioPharma(MREO.US) With Buy Rating, Maintains Target Price $8
Mereo BioPharma Group Analyst Ratings
Buy Rating Affirmed for Mereo Biopharma on Strong Financials and Promising Pipeline Progress
BTIG Maintains Mereo BioPharma(MREO.US) With Buy Rating, Maintains Target Price $6
Buy Rating Affirmed for Mereo Biopharma on Strong Clinical and Financial Prospects
Needham Reiterates Buy on Mereo BioPharma Group, Maintains $7 Price Target
Mereo BioPharma Group Analyst Ratings
Needham Maintains Mereo BioPharma(MREO.US) With Buy Rating, Maintains Target Price $7
Mereo BioPharma Group Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Mereo BioPharma Group, Maintains $7 Price Target